Send to

Choose Destination
Blood. 2019 May 21. pii: blood.2019000760. doi: 10.1182/blood.2019000760. [Epub ahead of print]

The Simpler the Better: Oral Arsenic for Acute Promyelocytic Leukemia.

Author information

Department of Hematology, the First Affiliated Hospital, College of Medicine, Zhejiang University, China.
Department of Hematology, Blood & Marrow Transplantation Center, Shanghai Institute of Hematology, China.
Department of Biopathology, University Tor Vergata, Italy.
The First Affiliated Hospital, Zhejiang University School of Medicine


Arsenic trioxide (ATO) and all-trans retinoic acid have become the front-line treatments for patients with acute promyelocytic leukemia (APL). Despite the long wait for an oral arsenic drug, a commercially available agent, "Realgar-Indigo naturalis formula (RIF)", was not launched in China until 2009. Since then, over 5000 patients with APL have been treated with oral RIF in China. Oral arsenic not only shows a clinical efficacy comparable to that of IV formulations but also displays a better safety profile, improved quality of life and lower medical costs for patients. The promising results promote incorporating an outpatient postremission therapy model into clinical practice for both low-risk and high-risk APL patients in China. In this review, we discuss the evolution of oral arsenic RIF in the treatment of APL, with a special focus on how to address the related complications during induction therapy.


Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center